Drug intelligence / Profile preview

Shulie'an Capsules

Development stage: Unknown
Lead developer: Yunnan Baiyao
Modality: Small Molecules
Administration: Oral

Overview

Shulie'an Capsules is a Traditional Chinese Medicine (TCM) product developed by Yunnan Baiyao Group, specifically formulated for the treatment of urological disorders. It is primarily indicated for chronic prostatitis and benign prostatic hyperplasia (BPH) characterized by 'damp-heat and blood stasis' in TCM theory. The formulation works to alleviate symptoms such as pelvic pain, urinary frequency, urgency, and painful urination by promoting blood circulation and clearing inflammatory heat. The product is approved in China and has undergone post-marketing clinical studies to validate its therapeutic efficacy and safety in urology patients.

Brand names: Shulie'an Capsules
Other names: Shulie'an Capsules舒列安胶囊

Beyond the preview

Go deeper on Shulie'an Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shulie'an Capsules.

Explore the full profile